Versant Capital Management, Inc Intra Cellular Therapies, Inc. Transaction History
Versant Capital Management, Inc
- $454 Million
- Q4 2024
A detailed history of Versant Capital Management, Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 136 shares of ITCI stock, worth $11,385. This represents 0.0% of its overall portfolio holdings.
Number of Shares
136
Previous 109
24.77%
Holding current value
$11,385
Previous $7,000
57.14%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ITCI
# of Institutions
378Shares Held
84.1MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$806 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$529 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$443 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$322 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$255 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $7.9B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...